Human papillomavirus type 16 E7 peptide-MHC complex (HPV16 E7 peptide-MHC complex)

The **Human papillomavirus type 16 E7 peptide-MHC complex** is formed when peptides derived from the E7 oncoprotein of HPV16, a high-risk virus responsible for many cervical and other anogenital cancers, bind to major histocompatibility complex (MHC) class I molecules on the surface of infected or transformed cells[1][2][3][4]. This complex is recognized by cytotoxic CD8+ T cells, enabling immune surveillance and targeted destruction of HPV-infected or HPV-transformed cells. The most widely studied epitope is YMLDLQPET (amino acids 11–19 of E7), recognized in the context of HLA-A*02:01 and related MHC class I alleles[1][3]. The HPV16 E7 peptide-MHC complex is a central immunological target for therapeutic vaccines, TCR-engineered cell therapies, and bispecific antibodies, aiming to drive robust anti-tumor immunity against HPV-associated cancers[4][5]. It is being investigated for use in immunotherapy, including candidate therapeutic vaccines and engineered immune cell therapies[5]. Potential clinical challenges include ensuring appropriate specificity, overcoming HLA-restriction barriers, and minimizing off-target effects due to molecular mimicry or cross-reactivity[3][5].

Other names

HPV16 E7/MHC complexHPV16 E7 antigen-MHC complexHPV16 E7 epitope-MHC class I complex

Induction of HPV16 E7-specific cytotoxic T lymphocyte response; Presentation of virally derived tumor antigen peptides to T cells via MHC class I molecules; Targeted by therapeutic antibodies or engineered T cell receptors that recognize the E7 peptide-MHC complex